Get Perinatal Hepb Program Manual

Neonatal hepatitis B virus infection is usually acquired during delivery. It is usually asymptomatic but can cause chronic subclinical disease in later childhood or adulthood. Symptomatic infection causes jaundice, lethargy, failure to thrive, abdominal distention, and clay-colored stools.

Babies born to mothers infected with hepatitis B need to be given a dose of the hepatitis B vaccine within 24 hours of their birth, followed by further doses at 4, 8, 12 and 16 weeks of age, plus a final dose when they're 1 year old.

The Perinatal Hepatitis B Prevention program (PHBPP) focuses on preventing the spread of hepatitis B virus from infected mothers to newborn infants. The Office of Immunization and Child Profile works with local health jurisdictions on tracking disease, case management, and education.

During pregnancy, the mother's viral load should be tested; if it is high (> 200,000 IU/mL (5.3 log10 IU/mL)), international and national guidelines recommend that third-trimester antiviral therapy with should be commenced (4, 5).

Perinatal HBV transmission can be prevented by identifying HBV-infected (i.e., hepatitis B surface antigen [HBsAg]-positive) pregnant women and providing hepatitis B immune globulin and hepatitis B vaccine to their infants within 12 hours of birth.

Babies born to mothers infected with hepatitis B need to be given a dose of the hepatitis B vaccine within 24 hours of their birth, followed by further doses at 4, 8, 12 and 16 weeks of age, plus a final dose when they're 1 year old.

The aim of the neonatal hepatitis B vaccine programme is to protect those infants, identified to be at risk through screening of their mothers, from becoming persistently infected with hepatitis B. a 12-month blood test to identify where immunisation has been unsuccessful at preventing transmission.

A test for HBsAg should be ordered at the first prenatal visit. Women with unknown HBsAg status or with new or continuing risk factors for HBV infection (eg, injection drug use or a sexually transmitted infection) should be screened at the time of admission to a hospital or other delivery setting.

The aim of the neonatal hepatitis B vaccine programme is to protect those infants, identified to be at risk through screening of their mothers, from becoming persistently infected with hepatitis B. a 12-month blood test to identify where immunisation has been unsuccessful at preventing transmission.